Transparency notification BlackRock, Inc.

Brussels (Belgium), 16 August 2018 – 20:00 (CEST) – regulated information

1. Summary of the notification
Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received a transparency notification from BlackRock, Inc. (having its registered office at 55 East 52nd Street, New York, NY, 10055, U.S.A.), dated 10 August 2018.

BlackRock, Inc. has notified that, following an acquisiation of UCB shares with voting rights and equivalent financial instruments by its affiliates, its total holding in UCB SA/NV has increased and has crossed the 5% threshold on 9 August 2018.

On 9 August 2018, BlackRock, Inc. (taking into account the holding of its affiliates) owned 9 149 508 UCB shares with voting rights (versus 9 035 664 shares in its previous notification), representing 4.70% of the total number of shares issued by the company (194 505 658) (versus 4.65% in its previous notification) as well as 615 324 equivalent financial instruments (versus 625 890 in its previous notification) representing 0.32% of the total number of shares issued by the company (same percentage as in its previous notification).

2. Content of the notification
The transparency notification dated 10 August 2018 includes the following information:

• Reason for the notification: Acquisition or disposal of voting securities or voting rights.
• Notification by: A parent undertaking or a controlling person.
• Persons subject to the notification requirement:

• Date on which the threshold is crossed: 9 August 2018.
• Threshold crossed (in %): 5%
• Denominator: 194 505 658.
• Notified details:

• Chain of controlled undertakings through which the holding is effectively held:
  Please see the full chain of control in the ‘Chain of Control’ tab.
• Additional information:
  The disclosure obligation arose due to total holding in voting rights for BlackRock, Inc. going above 5%.

3. Further information
This press release and the detailed transparency notification are available on UCB SA/NV’s website via the following link.
An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV’s website via the following link.

Investor Relations
Antje Witte,
Investor Relations, UCB    
T +32 2 559 94 14,
antje.witte@ucb.com

Isabelle Ghellynck,
Investor Relations, UCB
T +32 2 559 95 88,
isabelle.ghellynck@ucb.com

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 7 500 people in approximately 40 countries, the company generated revenue of € 4.5 billion in 2017. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news